Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.76 |
| ▸ | CA12 | O43570 | 2/20 | 0.68 |
| ▸ | CA9 | Q16790 | 2/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.58 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8789480 | 0.93 | CYP19A1 (0.78) | KEAP1CA12CA9CA1CA2 | |
| SCHEMBL407414 | 0.87 | KEAP1 (1.00) | KEAP1CA12CA9CA1CA2 | |
| SCHEMBL19358847 | 0.86 | CXCR4 (0.77) | KEAP1ALDH1A1SMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3516799 | 0.85 | KEAP1 (0.96) | KEAP1CA12CA9CA1CA2 | |
| SCHEMBL6140309 | 0.85 | KEAP1 (0.55) | KEAP1CA12CA9CA1CA2 | |
| SCHEMBL5960116 | 0.83 | MEN1 (0.73) | CA12CA9CYP19A1ALDH1A1MAPK1 | |
| SCHEMBL6271065 | 0.83 | ALDH1A1 (0.66) | KEAP1CA12CA9CA1CA2 | |
| SCHEMBL19554432 | 0.83 | ALDH1A1 (0.66) | KEAP1CA12CA9CA1CA2 | |
| SCHEMBL20946438 | 0.83 | CYP19A1 (0.69) | KEAP1CA12CA9CA1CA2 | |
| SCHEMBL1287434 | 0.83 | ALDH1A1 (0.70) | CA12CA9CYP19A1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118724765-A | Method for preparing sulfonamide derivative by using low-cost metal catalysis | 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) | 2024-10-01 | — | — | CN | disclosed |
| CN-112645852-B | Synthesis method for catalyzing reduction of imine into amine | 赣南医学院 | 2022-06-14 | — | — | CN | disclosed |
| CN-112645852-A | Synthesis method for catalyzing reduction of imine into amine | 赣南医学院 | 2021-04-13 | — | — | CN | disclosed |
| EP-2007760-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007108569-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-09-27 | — | — | WO | disclosed |
| US-7049468-B2 | Modulators of Rho C activity | ICONIX PHARMACEUTICALS, INC. (US) | 2006-05-23 | — | — | US | disclosed |
| EP-1453470-A4 | MODULATORS OF RHO C ACTIVITY | ICONIX PHARM INC (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20060025445-A1 | 11-Beta HSD1 inhibitors | WYETH | 2006-02-02 | — | — | US | disclosed |
| EP-1453470-A1 | MODULATORS OF RHO C ACTIVITY | Iconix Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030171341-A1 | Method for modulating the activity of a Rho C enzyme, comprising: contacting said Rho C enzyme with an effective amount of a compound of formula 1: | ENTELOS HOLDING CORP. | 2003-09-11 | — | — | US | disclosed |
| WO-2003043578-A2 | MODULATORS OF RHO C ACTIVITY | ICONIX PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171341-A1 | Method for modulating the activity of a Rho C enzyme, comprising: contacting said Rho C enzyme with an effective amount of a compound of formula 1: | RHOC, RHOA, ROCK1 | KEAP1 541/4885CA12 4463/4885CA9 2002/4885 |
| US-20060025445-A1 | 11-Beta HSD1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | KEAP1 921/4885CA12 2807/4885CA9 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.